Risperidone immunoassay
View Patent ↗Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
1. An immunoassay for detecting active pharmaceutically anti-psychotic drugs selected from the group consisting of risperidone, paliperidone and mixtures thereof comprising providing a mixture containing a sample, a conjugate of a carrier with a ligand having the formula:
wherein B is
Y is an organic spacing group;
X is a terminal functional group capable of binding to a carrier; and
p is an integer from 0 to 1;
and an antibody selectively reactive with said pharmaceutically active anti-psychotic drugs having little substantial reactivity with the pharmacologically inactive risperidone and paliperidone metabolite, 7-hydroxy-risperidone and having no substantial cross-reactivity with other pharmacologically inactive risperidone and paliperidone metabolites, said reactivity of said antibody with 7 hydroxy-risperidone being less than 40% and said cross reactivity of said antibody with the other pharmaceutically inactive metabolites being less than 5%, said reactivity and cross reactivity being based upon said antibody's combined reactivity with both risperidone and paliperidone,
and causing the pharmaceutically active anti-psychotic drug and said conjugate in said sample to bind with said antibody and thereafter measuring the amount of said conjugate in said sample that is bond or unbound to said antibody whereby the presence of the anti-psychotic drugs in said sample can be detected.
2. The immunoassay of claim 1 wherein the sample is a human sample.
3. The immunoassay of claim 2 wherein the presence of said pharmaceutically active anti-psychotic drug is quantified by measuring the amount of conjugate which is bound or unbound to said antibody.
4. The immunoassay of claim 3 wherein the pharmaceutically active anti-psychotic drugs are the selected from the group consisting of risperidone and paliperidone.
5. The immunoassay of claim 4 wherein said human sample is a sample taken from a patient treated with risperidone and said immunoassay measures the amount of risperidone and paliperidone in the sample.
6. The immunoassay of claim 5 wherein said human sample is as sample take from a patient treated with paliperidone and the immunoassay measures the amount of paliperidone in said sample.
7. The immunoassay of claim 1 wherein said antibody is generated from an immunogen comprising an immunogenic carrier containing polyamine polymer conjugated with a ligand of the formula:
8. The immunoassay of claim 3 , wherein the antibody is attached to a solid support.
9. The immunoassay of claim 8 , wherein the solid support is microtitor plates.
10. The immunoassay of claim 8 , wherein the solid support is nanoparticles.
11. The immunoassay of claim 7 , wherein said antibody is derived from mice, rabbits, sheep or rats.
12. The immunoassay of claim 11 , wherein said antibody is a monoclonal antibody.
13. A kit for determining the presence of pharmaceutical active anti-psychotic drugs selected from the group consisting of risperidone and paliperidone in a patient sample comprising separate reagents packaged in separate containers, one of said reagents being a conjugate of a carrier with a ligand of the formula:
wherein B is
Y is an organic spacing group;
X is a terminal functional group capable of binding to a carrier; and
p is an integer from 0 to 1;
and the other reagent being an antibody which is selectively reactive with a pharmaceutically active anti-psychotic drug selected from the group of consisting of risperidone and paliperidone wherein said antibody reacts with risperidone and paliperidone and has little substantial reactivity with the pharmacologically inactive risperidone and paliperidone metabolite, 7-hydroxy-risperidone, and does not substantial cross-reactivity with other pharmacologically inactive risperidone and paliperidone metabolites, said reactivity of said antibody with 7 hydroxy-risperidone being less than 40% and said cross reactivity of said antibody with the other pharmaceutically inactive metabolites being less than 5%, said reactivity and cross reactivity being based upon said antibody's combined reactivity with both risperidone and paliperidone.
14. The kit of claim 13 wherein p is 1.
15. The kit of claim 14 wherein B is —O—CH 2 —.
16. The kit of claim 15 where Y is lower alkylene.
17. The kit of claim 16 where X is
wherein R 3 is hydrogen, a halide, a hydroxyl, or taken together with its attached oxygen atom forms a reactive ester and R 4 is oxygen or sulfur.
18. The kit of claim 17 , wherein X is
19. The kit of claim 13 wherein Y is
wherein n and o are integers from 0 to 6, and m is an integer from 1 to 6.
20. The kit of claim 19 , wherein Y is